Interim report, May–October 2021/22

Second quarter

• Gross order intake amounted to SEK 4,045 M (3,627), corresponding to a 12 percent increase in constant currency
• Net sales were SEK 3,697 M (3,534), corresponding to a 7 percent growth in constant currency
• Gross margin amounted to 38.6 percent (40.9)
• EBIT amounted to SEK 533 M (559), corresponding to an EBIT margin of 14.4 percent (15.8)
• Earnings per share was SEK 1.00 (0.98) before/after dilution
• Cash flow after continuous investments decreased by SEK 379 M to SEK -17 M (362)

First six months

• Gross order intake amounted to SEK 8,025 M (8,078), corresponding to a 3 percent growth in constant currency
• Net sales were SEK 6,707 M (6,515), corresponding to a 7 percent increase in constant currency
• Gross margin amounted to 37.9 (43.2) percent
• EBIT amounted to SEK 734 M (893), corresponding to an EBIT margin of 10.9 percent (13.7)
• Earnings per share was SEK 1.33 (1.55) before/after dilution
• Cash flow after continuous investments decreased by SEK 749 M to SEK -360 M (389)

¹After continuous investments.
²Before/after dilution.
³Based on constant currency.

# # #

For further information, please contact:
Johan Adebäck, CFO, Elekta AB (publ)
Tel: +46 70 873 33 21, e-mail: [email protected]
Time zone: CET: Central European Time

Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: [email protected]
Time zone: CET: Central European Time

Kira Haapanen, IR Manager
Tel: +46 73 719 46 22, e-mail: [email protected]
Time zone: CET: Central European Time

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on November 25, 2021. (REGMAR)
 

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.